Burgos-Vargas Rubén, Abud-Mendoza Carlos, Díaz-Jouanen Efraín, Garza-Elizondo Mario A, Medrano-Ramírez Gabriel, Orozco-Alcalá Javier, Pacheco-Tena César, Pineda-Villaseñor Carlos, Carlos-Pozos Juan, Ramos-Niembro Francisco, Robles-San Román Manuel, Santana-Sahagún Ernesto
Servicio de Reumatología, Hospital General de México, Dr. Balmis 148, Col. Doctores, Del. Cuauhtémoc, 06720 México D.F., México.
Gac Med Mex. 2009 Jan-Feb;145(1):41-9.
We describe the guidelines for the current treatment of ankylosing spondylitis with an emphasis on the role and outlook of the Mexican rheumatologic community. The topics we analyze include: epidemiological as well as professional, financial, health status, and quality of life aspects. We propose to acknowledge that axial spondyloarthritis is the earliest form of ankylosing spondylitis. Finally we carry out a review of the literature supporting current therapeutic recommendations. Regarding the latter, we approached the ASAS/EULAR recommendations for the treatment of ankylosing spondylitis and their level of agreement with Mexican and other countries' rheumatologists. Finally, we analyzed the recommendations to start tumor necrosis alpha blockers among patients with ankylosing spondylitis.
我们阐述了当前强直性脊柱炎的治疗指南，重点关注墨西哥风湿病学界的作用和前景。我们分析的主题包括：流行病学以及专业、财务、健康状况和生活质量方面。我们建议承认轴向型脊柱关节炎是强直性脊柱炎的最早形式。最后，我们对支持当前治疗建议的文献进行了综述。关于后者，我们探讨了ASAS/EULAR关于强直性脊柱炎治疗的建议及其与墨西哥和其他国家风湿病学家的一致程度。最后，我们分析了在强直性脊柱炎患者中开始使用肿瘤坏死因子α阻滞剂的建议。
